Global Kidney Academy

Enhance your nephrology practice with CME and tools focused on kidney medicine.

Inside the IgAN Clinic: Shared Decision-Making Into Practice
Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CE
Inside the IgAN Clinic: Shared Decision-Making Into Practice
0.25 credits
- Jonathan Barratt, MD, PhD
0.25 credits
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
CME/CE In-Person Event
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
June 04, 2026
Glasgow
1.00 credit Learn more
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
CME/CE In-Person Event
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Glasgow
1.00 credit Learn more
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
CME/CE
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
0.25 credits
- Steven Fishbane, MD
- Maurizio Gallieni, MD
0.25 credits
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Nephrology
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
- Ellie Kelepouris, MD, FACP, FAHA
The Patient-Clinician Connection in Managing CKD-aP 
The Patient-Clinician Connection in Managing CKD-aP 
MinuteCE®
The Patient-Clinician Connection in Managing CKD-aP 
1.00 program credit
- James Burton, DM, FRCP
- Lucio Manenti, MD, PhD
1.00 program credit
Quantifying CKD-aP: Tools for Better Care 
Quantifying CKD-aP: Tools for Better Care 
MinuteCE®
Quantifying CKD-aP: Tools for Better Care 
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
Elevating CKD-aP Care: New Frontier 
Elevating CKD-aP Care: New Frontier 
MinuteCE®
Elevating CKD-aP Care: New Frontier 
1.00 program credit
- James Burton, DM, FRCP
- Lucio Manenti, MD, PhD
1.00 program credit

Programs

Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
CME/CE
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
0.25 credits
- Ellie Kelepouris, MD, FACP, FAHA
- Nihar R. Desai, MD, MPH
0.25 credits
CKD-aP: Beyond the Surface
CKD-aP: Beyond the Surface
MinuteCE®
CKD-aP: Beyond the Surface
1.00 program credit
- Leonie Kraft, MD
1.00 program credit
CKD-aP or Something Else? Decoding the Diagnosis
CKD-aP or Something Else? Decoding the Diagnosis
MinuteCE®
CKD-aP or Something Else? Decoding the Diagnosis
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
Is CKD-aP Hiding in Your Dialysis Center?
Is CKD-aP Hiding in Your Dialysis Center?
MinuteCE®
Is CKD-aP Hiding in Your Dialysis Center?
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
MinuteCE®
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
MinuteCE®
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
MinuteCE®
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD, MPH, MBA
1.00 program credit
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
MinuteCE®
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit

CME

MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
The Critical Interplay: CKD, HF, and HyperkaleAmia
The Critical Interplay: CKD, HF, and HyperkaleAmia
MinuteCE®
The Critical Interplay: CKD, HF, and HyperkaleAmia
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Potassium Binders in Practice: Clinical Trial Evidence
Potassium Binders in Practice: Clinical Trial Evidence
MinuteCE®
Potassium Binders in Practice: Clinical Trial Evidence
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Future Directions in Managing Hyperkalemia in CKD and HF
Future Directions in Managing Hyperkalemia in CKD and HF
MinuteCE®
Future Directions in Managing Hyperkalemia in CKD and HF
1.00 program credit
- Javed Butler, MD, MPH, MBA
- James Burton, DM, FRCP
1.00 program credit
Treatment Revolution in IgA Nephropathy
Treatment Revolution in IgA Nephropathy
Nephrology
Treatment Revolution in IgA Nephropathy
- Shikha Wadhwani, MD
- Dana Rizk, MD
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
CME/CE
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
0.25 credits
- Jonathan Barratt, MD, PhD
- Sydney Tang, MBBS, MD
0.25 credits
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Cardiology
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
- Stefan D. Anker, MD, PhD
- Mahir Karakas, MD, PhD, MBA
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
CME/CE
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
- Thilo Krüger, MD, PhD
- Steven Fishbane, MD
- Lucio Manenti, MD, PhD

Global Kidney Academy

Popular

Programs

CME

Title

Share on ReachMD

Welcome to Global Kidney Academy

Welcome to Global
Kidney Academy